Ferrer offers $122M biobucks for ex-US license to Verge ALS drug
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI)...
VRG50635, a small molecule PIKfyve inhibitor, is one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform Verge™s proof-of-concept study...
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI)...
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data,...
Verge Genomics and the Pritzker Neuropsychiatric Disorders Research
Verge Genomics has secured its largest deal yet, linking up with AstraZeneca’s rare disease division Alexion in a deal worth up to $882 million.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Verge Genomics, a clinical-stage biotechnology company transforg drug discovery using artificial intelligence and human data, today announced the completion of the Phase 1 clinical trial of VRG50635 in healthy adult volunteers. VRG50635 was dosed up to the maximum single and repeated doses planned, demonstrating a favorable safety, tolerability, and pharmacokinetic profile supportive of advancement into a proof-of-concept study in people with amyotrophic lateral sclerosis (ALS). Detailed results from the study will be presented at the upcog European Network to Cure ALS (ENCALS) 2023 meeting being held in Barcelona, Spain from July 12-14, 2023.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Verge Genomics, a clinical-stage, biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced today that Robert H. Scannevin, Ph.D., Chief Scientific Officer, will join other experts in a panel discussion regarding the latest trends in brain health, at the Mass General Brigham and Bank of America World Medical Innovation Forum in Boston on June 12, 2023.
Verge Genomics Appoints Diego Cadavid, M.D., as Chief Medical Officer